Update On Phase 3 Librexia ACS Trial

RefinitivMeno di 1 minuto di lettura

Bristol-Myers Squibb Co BMY:

UPDATE ON PHASE 3 LIBREXIA ACS TRIAL
BRISTOL-MYERS SQUIBB CO - LIBREXIA ACS TRIAL DISCONTINUED DUE TO EFFICACY CONCERNS
BRISTOL-MYERS SQUIBB CO - NO NEW SAFETY CONCERNS IDENTIFIED FOR MILVEXIAN
BRISTOL-MYERS SQUIBB CO - LIBREXIA AF AND STROKE STUDIES CONTINUE, DATA EXPECTED 2026

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Accedi o crea un account gratuito per leggere queste notizie